Neoplasms

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Neoplasm Metastasis

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Herbal and Botanical

Cetuximab

Cola

Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment

Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment

targeted substance according to the avatar model

Sebastian Stintzing, Prof. Dr.

In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated. Therefore, tumor material of all patients shall be obtained, transferred into avatars and treated the same way as in the patient until resistance arises. These resistant tumor cells are subsequently treated by different targeted treatment combinations in the mouse avatar model to find the most active drug or combination of drugs. This drug or combination of drugs may then be offered to the patient after cetuximab resistance has occurred. Multiple liquid biopsies shall be obtained in patients during first-line treatment with cetuximab as well as during second line experimental treatment to monitor mutations that may be associated with cetuximab resistance. Furthermore at the time of resistance a biopsy should be taken and analyzed to ensure that the mechanism of resistance seen in the avatar model matches with the mechanism of resistance in the individual patient.

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)

MGO Ruhr-University Bochum (RUB)

PD Dr. med. Volker Heinemann

Director of the CCC LMU

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model	NCT03263663	Colo-rectal Can... RAS Wild-type UICC III UICC II + RF UICC IV Curativ...	targeted substa...	18 Years -	Ludwig-Maximilians - University of Munich
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model	NCT03263663	Colo-rectal Can... RAS Wild-type UICC III UICC II + RF UICC IV Curativ...	targeted substa...	18 Years -	Ludwig-Maximilians - University of Munich
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model	NCT03263663	Colo-rectal Can... RAS Wild-type UICC III UICC II + RF UICC IV Curativ...	targeted substa...	18 Years -	Ludwig-Maximilians - University of Munich

Spots Global Cancer Trial Database for uicc iv curative intent